BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jan 10, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

ZGN-433: Phase Ib data

Top-line data from a double-blind, placebo-controlled, multiple-ascending dose, Australian Phase Ib trial in 24 severely obese females showed that 0.9 mg/m 2 twice-weekly IV ZGN-433 was well tolerated...

Read the full 116 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >